Renaissance Technologies LLC Purchases 491,700 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Renaissance Technologies LLC grew its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 463.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 597,810 shares of the company's stock after buying an additional 491,700 shares during the quarter. Renaissance Technologies LLC owned 0.77% of Kura Oncology worth $5,207,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in KURA. Harbor Advisors LLC bought a new stake in Kura Oncology during the 4th quarter valued at $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the 4th quarter worth approximately $90,000. Corient Private Wealth LLC bought a new stake in Kura Oncology during the 4th quarter valued at $109,000. Teacher Retirement System of Texas boosted its holdings in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after acquiring an additional 2,285 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in Kura Oncology in the fourth quarter worth about $127,000.

Kura Oncology Price Performance

Kura Oncology stock traded up $0.13 during midday trading on Tuesday, reaching $6.31. 1,010,347 shares of the company were exchanged, compared to its average volume of 1,146,671. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a market capitalization of $509.71 million, a price-to-earnings ratio of -2.67 and a beta of 0.83. The firm's 50-day simple moving average is $6.99 and its 200-day simple moving average is $10.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts' expectations of $57.96 million. On average, analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 in the last quarter. Insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

KURA has been the topic of a number of recent research reports. Scotiabank cut their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. JMP Securities restated a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.